Literature DB >> 23705124

Spinal Cord Injury due to the Giant Cell Tumor of the Second Thoracic Vertebra: A Case Report.

Hee-Sang Kim1, Jong Eon Lee, Sang Soo Jung, Jinmann Chon, Dong Hwan Yoon, Yong-Koo Park, Eun Hye Cho.   

Abstract

Giant cell tumor (GCT) is a relatively rare neoplasm. In GCT, the bone affection of the axial skeleton is extremely rare. Most GCT arises in the meta-epiphyseal ends of the long bones. Its peak incidence is between 30 to 40 years of age. GCT is usually classified as benign, but shows locally aggressive behavior and may occasionally undergo a malignant transformation. The patients with GCT in the spine often complain of the lower back pains, as the tumors primarily involve the sacrum. We report a case of an adolescent female complaining of the upper back pain with a sudden weakness of the lower extremities, later diagnosed with the GCT of the T2 vertebra. The present patient showed American Spinal Injury Association Impairment Scale (AIS) D before the surgery, which changed to AIS E after the treatments including the surgery, radiation therapy and rehabilitation.

Entities:  

Keywords:  Giant cell tumor; Spinal cord injuries

Year:  2013        PMID: 23705124      PMCID: PMC3660490          DOI: 10.5535/arm.2013.37.2.269

Source DB:  PubMed          Journal:  Ann Rehabil Med        ISSN: 2234-0645


  8 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

Review 2.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.

Authors:  Christopher Martin; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2010

3.  Giant-cell tumors of the cervical spine: case report.

Authors:  Christopher L Hunter; Donato Pacione; Mark Hornyak; Raj Murali
Journal:  Neurosurgery       Date:  2006-11       Impact factor: 4.654

Review 4.  Spinal cord injury medicine. 3. Rehabilitation phase after acute spinal cord injury.

Authors:  Steven C Kirshblum; Michael M Priebe; Chester H Ho; William M Scelza; Anthony E Chiodo; Lisa-Ann Wuermser
Journal:  Arch Phys Med Rehabil       Date:  2007-03       Impact factor: 3.966

Review 5.  Giant cell tumor of the thoracic spine: case report and review of the literature.

Authors:  Daniel Refai; Gavin P Dunn; Paul Santiago
Journal:  Surg Neurol       Date:  2008-01-22

Review 6.  Giant cell tumor of bone.

Authors:  William M Mendenhall; Robert A Zlotecki; Mark T Scarborough; C Parker Gibbs; Nancy P Mendenhall
Journal:  Am J Clin Oncol       Date:  2006-02       Impact factor: 2.339

7.  Giant-cell tumours of the spine.

Authors:  B K Sanjay; F H Sim; K K Unni; R A McLeod; R A Klassen
Journal:  J Bone Joint Surg Br       Date:  1993-01

8.  Giant cell tumors of the axial skeleton.

Authors:  Maurice Balke; Marcel P Henrichs; Georg Gosheger; Helmut Ahrens; Arne Streitbuerger; Michael Koehler; Viola Bullmann; Jendrik Hardes
Journal:  Sarcoma       Date:  2012-02-08
  8 in total
  4 in total

1.  Giant cell tumor of the thoracic spine causing acute paraplegia-a case report.

Authors:  Christopher Lucasti; Dil Patel; Bradley Hawayek; Mark Maraschiello; Joseph Kowalski
Journal:  J Spine Surg       Date:  2021-06

2.  Obstructive hydrocephalus as a result of giant cell tumor of the thoracic spine: A case report.

Authors:  Cheng-Yu Wei; Shuo-Tsung Chen; Hsu-Chih Tai; Wen-Bing Wang; Chi-Chu Chang; Yao-Chin Wang; L I Wei; Woon-Man Kung
Journal:  Oncol Lett       Date:  2015-11-06       Impact factor: 2.967

3.  Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor.

Authors:  Daisuke Kajiwara; Hiroto Kamoda; Tsukasa Yonemoto; Shintaro Iwata; Takeshi Ishii; Toshinori Tsukanishi; Seiji Ohtori; Masashi Yamazaki; Akihiko Okawa
Journal:  Asian Spine J       Date:  2016-06-16

4.  Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report.

Authors:  Ping-Guo Duan; Yong-Hong Sheng; Chang-Hao Deng; Ben-Yu Tang; Hao-Qun Yao
Journal:  BMC Musculoskelet Disord       Date:  2020-02-15       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.